Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business expansion.